ANEB
Anebulo Pharmaceuticals Inc

183
Mkt Cap
$94.49M
Volume
7,142.00
52W High
$3.42
52W Low
$0.8001
PE Ratio
-9.77
ANEB Fundamentals
Price
$2.29
Prev Close
$2.30
Open
$2.47
50D MA
$2.47
Beta
0.34
Avg. Volume
21,231.65
EPS (Annual)
-$0.2509
P/B
9.70
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·7d ago
News Placeholder
More News
News Placeholder
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·9mo ago
News Placeholder
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the Company or...
Business Wire·11mo ago
News Placeholder
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·1y ago
News Placeholder
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·1y ago
News Placeholder
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute...
Business Wire·2y ago
News Placeholder
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 4,600...
Ticker Report·2y ago
News Placeholder
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 18.2%
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB Get Free Report) was the recipient of a significant decline in short interest in January. As of January 31st, there was short interest totalling...
Ticker Report·2y ago
News Placeholder
Anebulo Pharmaceuticals price target lowered by $2 at Ladenburg, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. What's the Latest?
Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Debt & Financing category. Anebulo Pharmaceuticals, Inc. has undertaken a sig...
TipRanks Financial Blog·2y ago

Latest ANEB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.